Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant nivolumab with or without NKTR-214 versus surgery alone in cisplatin-ineligible muscle-invasive bladder cancer
MOH_2019-05-12_006092Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and bempegaldesleukin in bladder cancer and muscle-invasive bladder cancer (MIBC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Pathologic response rate and Event-free survival. Started Apr 2019; status: completed.
02
Drugs
nivolumabbempegaldesleukin
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on MOH_2019-05-12_006092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-12_006092.